19.07.2021 • News

Verdant Strengthens Surfactants with First Acquisition

Verdant Specialty Solutions, Solvay’s former amphoteric surfactants business, has acquired DeForest Enterprises and ParaFlow Energy Solutions from Chemical Services Group for an undisclosed sum.

The acquisition, said Verdant, marks an important first step in its strategy to accelerate growth through accretive acquisitions in existing and adjacent technologies and markets. Verdant CEO John Foley commented: “These two acquisitions expand our portfolio of surfactants so that we can help customers across a broader range of markets find creative solutions and capitalize on new opportunities.”

DeForest Enterprises is a specialty surfactants company while ParaFlow Energy Solutions provides products for paraffin mitigation in upstream crude oil production and technologies for use in demulsifier applications.

Both companies are based in Boca Raton, Florida, USA, and together supply more than 100 customers in markets including industrial and institutional cleaning, metalworking and metal finishing, oilfield, pigments and inks, construction and automotive care.

Verdant is a portfolio company of global private equity group OpenGate Capital, which bought Solvay’s secondary surfactants business on Apr. 30 and renamed it. Verdant employs approximately 175 staff and operates three main production sites in University Park, Illinois, USA; Halifax, UK, and Genthin, Germany, as well as a tolling business in Turkey. It is headquartered in Houston, Texas, USA.

Author: Elaine Burridge, Freelance Journalist

Verdant Specialty Solutions, Solvay’s former amphoterics surfactants...
Verdant Specialty Solutions, Solvay’s former amphoterics surfactants business, has bought DeForest Enterprises and ParaFlow Energy Solutions, making a first step in its strategy to accelerate growth through accretive acquisitions in existing and adjacent technologies and markets. (c) Verdant Specialty Solutions

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

most read